HealthInvest Partners AB Boosts Stock Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)

HealthInvest Partners AB grew its holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) by 41.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 98,304 shares of the biopharmaceutical company’s stock after purchasing an additional 28,731 shares during the period. HealthInvest Partners AB’s holdings in Corbus Pharmaceuticals were worth $1,188,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. State Street Corp lifted its position in shares of Corbus Pharmaceuticals by 34.6% during the third quarter. State Street Corp now owns 595,576 shares of the biopharmaceutical company’s stock worth $12,287,000 after acquiring an additional 153,243 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Corbus Pharmaceuticals by 8.1% during the 3rd quarter. Geode Capital Management LLC now owns 249,759 shares of the biopharmaceutical company’s stock valued at $5,154,000 after purchasing an additional 18,702 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Corbus Pharmaceuticals by 224.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 93,643 shares of the biopharmaceutical company’s stock worth $1,932,000 after purchasing an additional 64,800 shares in the last quarter. HighVista Strategies LLC boosted its stake in Corbus Pharmaceuticals by 94.1% in the 3rd quarter. HighVista Strategies LLC now owns 75,292 shares of the biopharmaceutical company’s stock worth $1,553,000 after purchasing an additional 36,499 shares during the period. Finally, Wexford Capital LP grew its holdings in Corbus Pharmaceuticals by 55.3% during the 3rd quarter. Wexford Capital LP now owns 68,556 shares of the biopharmaceutical company’s stock valued at $1,414,000 after buying an additional 24,400 shares in the last quarter. 64.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CRBP. StockNews.com upgraded shares of Corbus Pharmaceuticals to a “sell” rating in a research report on Monday, January 13th. Wedbush restated an “outperform” rating and set a $51.00 price target on shares of Corbus Pharmaceuticals in a research report on Monday, November 4th. Piper Sandler started coverage on Corbus Pharmaceuticals in a research report on Monday, December 2nd. They issued an “overweight” rating and a $35.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Corbus Pharmaceuticals in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $61.38.

Corbus Pharmaceuticals Stock Down 1.2 %

NASDAQ CRBP opened at $8.18 on Monday. The stock’s 50-day simple moving average is $11.21 and its two-hundred day simple moving average is $23.84. Corbus Pharmaceuticals Holdings, Inc. has a twelve month low of $7.64 and a twelve month high of $61.90. The company has a market capitalization of $99.63 million, a price-to-earnings ratio of -1.74 and a beta of 2.63.

Corbus Pharmaceuticals Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.